MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth is viewed favorably because it has become a more focused prostate cancer diagnostics pure play after discontinuing Resolve, removing the $10.4 million Novitas liability claim and sharpening attention on higher-quality growth drivers. The August 2025 Exosome Diagnostics acquisition for $15 million, expected to add $20 million+ of revenue in 2026, strengthens its liquid biopsy offering and supports the company’s leadership in a urology market expected to grow 5%-10%+ over the coming years. Combined with Q2’26 revenue of $27.2 million, +16% year over year, pro-forma cash of about $39 million, and a path toward positive adjusted EBITDA in Q4’26 and ~20% margin by exiting 2028, the setup suggests improving scale, de-risking, and operating leverage.

MDxHealth is facing a deteriorating fundamental profile after pre-announcing a Q3 revenue miss to $22.7M, with tissue volumes of 11,232 and liquid-based test volumes of 11,792 both below expectations, signaling weaker commercial execution than anticipated. The company said the shortfall stemmed from unexpected sales rep turnover after winding down Resolve UTI earlier in 2026, but suspending its 2026 revenue guidance despite less than three months remaining undermines confidence in management’s visibility and growth trajectory. Balance-sheet risk adds to the pressure, with cash of $31.7M against $18M and $21M contingent consideration payments due in 2027 and 2028, alongside other liabilities, making recovery dependent on a sales rebound and tighter capital management.